ORION OYJ |
Market Closed -
Other stock markets
|
After market 03:59:59 pm | |||
| 37.01 EUR | -1.52% |
|
37.05 | +0.11% |
| May. 07 | Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 | CI |
| Apr. 26 | Orion Corporation Announces Appointments to Nomination Committee | CI |
| Sales 2024 * | 1.38B 1.5B | Sales 2025 * | 1.45B 1.58B | Capitalization | 5.29B 5.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 242M 263M | Net income 2025 * | 250M 272M | EV / Sales 2024 * | 3.81 x |
| Net cash position 2024 * | 46.22M 50.25M | Net cash position 2025 * | 3.2M 3.48M | EV / Sales 2025 * | 3.65 x |
| P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
21.2
x | Employees | 3,698 |
| Yield 2024 * |
4.46% | Yield 2025 * |
4.55% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | -1.48% | ||
| 1 week | -0.78% | ||
| Current month | +3.41% | ||
| 1 month | +1.87% | ||
| 3 months | +0.03% | ||
| 6 months | +1.20% | ||
| Current year | -5.76% |
1 week
36.81
37.80
1 month
35.5438.20
Current year
31.8645.29
1 year
31.8645.29
3 years
31.8655.16
5 years
28.7655.16
10 years
22.5758.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Chief Operating Officer | - | 15-12-31 | |
Outi Vaarala
CTO | Chief Tech/Sci/R&D Officer | 62 | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 664 M€ | +9.73% | ||
| 2.87% | 473 M€ | +6.93% | ||
| 0.35% | 1,083 M€ | +4.30% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 37.01 | -1.52% | 206 846 |
| 24-05-27 | 37.58 | +0.64% | 115,774 |
| 24-05-24 | 37.34 | -0.69% | 132,385 |
| 24-05-23 | 37.6 | +0.13% | 91,357 |
| 24-05-22 | 37.55 | +0.67% | 119,070 |
Delayed Quote Nasdaq Helsinki, May 28, 2024 at 11:29 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.58
EUR
Average target price
39
EUR
Spread / Average Target
+3.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.76% | 5.75B | |
| +38.04% | 727B | |
| -7.80% | 354B | |
| +15.75% | 328B | |
| -0.32% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.00% | 164B | |
| -2.17% | 164B |
- Stock Market
- Equities
- ORNBV Stock
